ADC Therapeutics SA Common Shares (ADCT)
1.7400
0.00 (0.00%)
Adc Therapeutics is a biotechnology company focused on the development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancers
The company leverages its proprietary technology platform to create innovative therapies that specifically target and kill cancer cells while sparing healthy tissue, thereby enhancing treatment efficacy and reducing side effects. Adc Therapeutics aims to address unmet medical needs in oncology by advancing its pipeline of drug candidates through clinical trials, and its research efforts are guided by a commitment to improve patient outcomes in various types of malignancies.
![](https://cdn.benzinga.com/files/images/story/2024/11/08/ADCT.png?width=1200&height=800&fit=crop)
Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a promising oncology pipeline. Overweight rating, $6 price target.
Via Benzinga · November 8, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
![](https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_03.jpg)
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential.
Via InvestorPlace · July 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/07/08/wall-street-ai9.png?width=1200&height=800&fit=crop)
Via Benzinga · July 8, 2024
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
Via InvestorPlace · June 13, 2024
![](https://cdn.pixabay.com/photo/2020/11/27/16/59/man-5782411_960_720.jpg)
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors.
Via Talk Markets · February 27, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 6, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/06/xrdDAFefWvBGaQ2-j1684620644-t23032813.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 6, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/30/Image32.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · April 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/13/tesla_-_logo.jpg?width=1200&height=800&fit=crop)
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.
Via Benzinga · March 13, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQSGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via Benzinga · March 13, 2024
![](https://cdn.benzinga.com/files/images/story/2024/02/20/alaska_air_group_-_logo.jpg?width=1200&height=800&fit=crop)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · February 20, 2024
![](https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3.jpg)
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via InvestorPlace · February 15, 2024
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Via InvestorPlace · February 8, 2024
![](https://cdn.benzinga.com/files/images/story/2023/11/06/image14.jpg?width=1200&height=800&fit=crop)
Gainers Carbon Revolution Public Limited (NASDAQCREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
Via Benzinga · November 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 10, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
On Tuesday, 56 companies set new 52-week lows.
Via Benzinga · July 25, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
On Friday, 54 companies hit new 52-week lows.
Via Benzinga · July 21, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
On Monday morning, 70 companies achieved new lows for the year.
Via Benzinga · July 24, 2023